Healthcare Press

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma - Nature Medicine

  • 📰 NatureMedicine
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 53%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Multi-omics analysis of tumors from phase 1b GO30140 and phase 3 IMbrave150 trials reveals immune and genetic features in patients with advanced hepatocellular carcinoma who might benefit from atezolizumab and bevacizumab combination therapy genentech

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Kaplan-Meier estimates of progression-free survival and overall survival in patients in the ITT and BEP of, IMbrave150 . Stratified hazard ratios and two-sided log-likelihoodvalues for progression or death are reported. 95% confidence intervals are indicated in parentheses.

Extended Data Fig. 3 Key biomarker expression by RECIST response and PFS/OS association within treatment groups of IMbrave150., Expression of ABRS, CD274 and Teff signature score by RECIST response in IMbrave150 Atezo-Bev treatment group . Box plots are of log2 gene expression scores for response categories, with two-sided P values from Student t tests. Boxes represent median and first/third quartile values. Box whiskers represent the most extreme values within 150% of the interquartile range.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 451. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

The promise of precision medicine in rheumatology - Nature MedicinePrecision medicine for rheumatic diseases is still in its infancy, but recent advances are enabling comprehensive profiling and mechanistic insights. This Review outlines the progress, promises, and challenges of translating these findings into the clinic. OMRF We must stop hurting patients on a daily basis and implement pharmacogenetics now. DoNoHarm cpicpgx
Source: NatureMedicine - 🏆 451. / 53 Read more »

A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs - Nature BiotechnologyA multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs OHSUNews OHSUKnight BrighamWomens harvardmed is it a reliable source of information? Research Briefing: Identifying drug combinations that enhance treatment responses mediated by the tumor microenvironment OHSUNews OHSUKnight BrighamWomens harvardmed This is really cool
Source: NatureBiotech - 🏆 231. / 63 Read more »